Top Markets
Coin of the day
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
Clasificación en acciones #5675
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
Precio por acción
$62.49
Última sincronización: 2024-03-06
Capitalización bursátil
$2.52B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio RayzeBio, Inc. Common Stock (RYZB)

Categoría

Historial de dividendos de RayzeBio, Inc. Common Stock (RYZB)
RayzeBio, Inc. Common Stock (símbolo bursátil: RYZB) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de RayzeBio, Inc. Common Stock (RYZB) desde 2026 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
Not enough data for the provided dates.
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
Not enough data for the provided dates.
Pagos de dividendos de empresas similares o competidoras
Empresa Número de pagos de dividendos País
0.00%
US
0.00%
NL
0.00%
US
64.00%
AU
0.00%
CH